康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01681 康臣药业

已收盘 09-09 16:08:06

13.150

-0.040

-0.30%

最高13.330	最低13.060	成交量154.50万
今开13.180	昨收13.190	日振幅2.05%
总市值110.33亿	流通市值110.33亿	总股本8.39亿
成交额2,031万	换手率0.18%	流通股本8.39亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01681","market":"HK","secType":"STK","nameCN":"康臣药业","latestPrice":13.15,"timestamp":1788941286003,"preClose":13.19,"halted":0,"volume":1545000,"delay":0,"changeRate":-0.0030326004548900036,"floatShares":839000000,"shares":839000000,"eps":1.473718592176668,"marketStatus":"已收盘","change":-0.04,"latestTime":"09-09 16:08:06","open":13.18,"high":13.33,"low":13.06,"amount":20311720,"amplitude":0.02047,"askPrice":13.16,"askSize":8000,"bidPrice":13.15,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":1.6146131072963394,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789003800000},"marketStatusCode":5,"adr":0,"listingDate":1387382400000,"exchange":"SEHK","adjPreClose":13.19,"dividendRate":0.060602,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":1.23161,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01681","defaultTab":"news","newsList":[{"id":"1118321439","title":"康臣药业2026年8月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1118321439","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118321439?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:36","pubTimestamp":1788262590,"startTime":"0","endTime":"0","summary":"2026年9月1日，康臣药业集团有限公司公布截至2026年8月31日的股份变动月报。报告期内，公司法定注册股本维持5,000,000,000股，对应股本总额约5亿港元，无新增或减少。在股权激励方面，2013年12月2日采纳的购股权计划上月底结存7,074,153份股份期权，于本月内全部变动，8月底余额为0；2024年5月31日采纳的购股权计划尚未有变动，目前可发行或转让的潜在股份总数为84,281,191股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729891","title":"港股公告掘金 | 利润同比增加98.28%接近翻倍，不同集团发布上半年业绩公告，计划加大核心产品的AI升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729891","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729891?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:07","pubTimestamp":1787792839,"startTime":"0","endTime":"0","summary":"重大事项：百度集团-SW(09888)：于香港联交所自愿转换为双重主要上市中国宝力科技(00164)于蒙古部署其干磨干选业务方面取得重大进展博安生物(06955)：BA2201(TL1A/IL-23)临床试验申请获CDE受理康希诺生物(06185)附属与德普世生物订立mRNA个性化治疗型肿瘤疫苗共同开发战略合作框架协议石药集团(01093)：SYS6010用于EGFR TKI治疗失败的EGFR突变","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09888","LU0359202008.SGD","LU0531971595.HKD","LU0456827905.SGD","AIPO","LU0821914370.USD","BK1191","ARTY","LU0543330566.HKD","LU0043850808.USD","CHAT","BIDU","IE00B3M56506.USD","LU2476274308.USD","LU0287142896.SGD","LU0163747925.USD","BK1193","BK1258","BK1575","AGIX","LU0229945570.USD","KCAI","SG9999002463.SGD","TCHI","HK0000306685.HKD","VTHR","QTOC","LU0823426480.USD","LU0164865239.USD","LU0359201612.USD","LU0856984785.SGD","01681","LU0417516902.SGD","LU0197773673.USD","LU1115378108.SGD","LU1188198961.HKD","HK0000320264.USD","LU0052750758.USD","LU0630378429.USD","BK4585","LU0307460666.USD","00164","BK1207","06090","89888","LU0244354667.USD","00836","LU0708995583.HKD","LU0315179316.USD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662936837","title":"港股异动丨康臣药业午后直线拉升大涨14% 股价创逾3个月新高 上半年纯利同比增长19.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662936837","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662936837?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:17","pubTimestamp":1787728622,"startTime":"0","endTime":"0","summary":"康臣药业午后直线拉升，一度放量大涨13.96%至15.27港元，股价创今年5月8日以来逾3个月新高。　　消息面上，康臣药业今日午间公布中期业绩，期内实现收入17.85亿元，同比增加约13.8%；公司权益股东应占溢利为5.95亿元，同比增加约19.5%。　　按产品系列分类，肾科系列产品销售较2025年同期增长约18.1%，继续保持市场领先地位。妇儿系列产品及肝胆系列产品销售分别增长约9.1%及233.7%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/26/20260826627763.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/26/20260826627763.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260826/32348014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["KCAI","BK1606","BK1191","VXUS","BK4585","BK4588","01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662767445","title":"港股异动 | 康臣药业绩后涨超7%，中期股东应占溢利同比增近两成，肾科系列产品市销保持行业领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2662767445","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662767445?lang=zh_cn&edition=full","pubTime":"2026-08-26 14:00","pubTimestamp":1787724015,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，$康臣药业$绩后涨超7%。消息面上，8月26日午间，康臣药业发布截至2026年6月30日止6个月业绩，该集团期内取得收入17.85亿元人民币，同比增加13.8%；公司权益股东应占溢利5.95亿元，同比增加19.5%；每股基本盈利0.71元；拟派发中期股息每股0.38港元。于2026年上半年，本集团的毛利为人民币14.52亿元，与2025年同期的人民币12.09亿元相比，增长约20.1%。按产品系列分类，肾科系列产品销售较2025年同期增长约18.1%，继续保持市场领先地位。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485845.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1191","01681","KCAI","BK4588","BK1606","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662767410","title":"港股异动 | 康臣药业(01681.HK)绩后涨超11% 中期股东应占溢利同比增近两成 肾科系列产品市销保持行业领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2662767410","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662767410?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:39","pubTimestamp":1787722744,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01681","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662767506","title":"康臣药业（01681）绩后涨逾11% 中期营收、利润均录得双位数增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662767506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662767506?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:21","pubTimestamp":1787721710,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康臣药业（01681）绩后股价涨逾11%，最新报14.90港元，涨11.49%，成交额5142.82万港元。消息面上，公司午间公布截至2026年6月30日止六个月的中期业绩，股东应占溢利5.95亿元人民币，同比增长19.47%；每股基本盈利0.71元人民币。期内，营收17.85亿元人民币，同比增长13.78%。集团整体收入增长主要源于其持续致力于拓展全国销售网络，以及提升产品的市场覆盖率。期内，毛利14.52亿元人民币，同比增长20.14%，主要是由于销售增长所致；平均毛利率约为81.4%，与2025年同期的77.1%相比，增长4.3个百分点。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989527","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662662762","title":"康臣药业(01681)将于10月8日派发中期股息每股0.38港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662662762","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662662762?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:43","pubTimestamp":1787719395,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)发布公告，将于2026年10月8日派发截至2026年6月30日止六个月的中期股息每股0.38港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1606","VIG","BK1191","EWH","01681","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662018764","title":"康臣药业(01681)发布中期业绩 股东应占溢利5.95亿元 同比增加19.5% 肾科系列产品销售同比增长约18.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662018764","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662018764?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:23","pubTimestamp":1787718212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业 发布截至2026年6月30日止6个月业绩，该集团期内取得收入17.85亿元人民币，同比增加13.8%;公司权益股东应占溢利5.95亿元，同比增加19.5%;每股基本盈利0.71元;拟派发中期股息每股0.38港元。妇儿系列产品及肝胆系列产品销售分别增长约9.1%及233.7%。于2026年上半年，本集团的毛利为人民币14.52亿元，与2025年同期的人民币12.09亿元相比，增长约20.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业(01681)发布中期业绩 股东应占溢利5.95亿元 同比增加19.5% 肾科系列产品销售同比增长约18.1%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155197515","title":"康臣药业（01681）派发2026财年中期股息每股0.38港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155197515","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155197515?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:15","pubTimestamp":1787717743,"startTime":"0","endTime":"0","summary":"香港时间2026年8月26日，康臣药业集团有限公司公告，董事会已宣派截至2026年6月30日止六个月的中期股息，每股派发0.38港元，股息性质为普通股息。公司财年结算日为2026年12月31日。股息时间表如下：除净日为2026年9月8日；登记过户文件最后递交时间为2026年9月9日16:30；记录日期为2026年9月9日；股息派发日定于2026年10月8日。股息派发货币为港元，兑换率为1港元兑1港元。公告同时指出，本次股息不涉及代扣所得税。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100003652","title":"康臣药业（01681）2026年中期净利同比增19.5%至5.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100003652","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100003652?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:05","pubTimestamp":1787717145,"startTime":"0","endTime":"0","summary":"2026年8月26日，康臣药业集团有限公司公布截至2026年6月30日止六个月未经审计中期业绩。报告期内，公司收入为17.85亿元，同比增长13.8%；毛利为14.52亿元，同比增长20.1%。\\n\\n期内，公司权益股东应占溢利为5.95亿元，同比增加19.5%。基本每股收益0.71元，摊薄每股收益0.70元，分别同比增长20.3%及20.7%。所得税费用1.00亿元，同比增加209.3%。\\n\\n资产负债表显示，截至2026年6月30日，公司总资产68.32亿元；流动资产46.66亿元，其中现金及现金等价物12.69亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145182829","title":"财报前瞻 ｜康臣药业本季度营收预测缺失，机构观点待观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1145182829","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145182829?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:20","pubTimestamp":1787102410,"startTime":"0","endTime":"0","summary":"康臣药业将于2026年08月26日发布财报，围绕处方药与中成药组合的盈利韧性、费用投入节奏与产品结构升级将是市场关注重点。由于缺乏可得的一致预期数据与公司披露的前瞻口径，本季度针对康臣药业的营收、毛利率、净利润或净利率、调整后每股收益的具体预测及同比信息暂无权威数据可披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜康臣药业本季度营收预测缺失，机构观点待观察","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108081460","title":"康臣药业：FIDELITY INVESTMENT TRUST增持，好仓比例升至5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108081460","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108081460?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:13","pubTimestamp":1787044428,"startTime":"0","endTime":"0","summary":"FIDELITY INVESTMENT TRUST于2026年8月13日以每股均价13.8018港元买入康臣药业股份11.30万股，涉资约155.96万港元。FIDELITY INVESTMENT TRUST此次增持前持有康臣药业好仓4199.73万股，占比4.99%；增持后持股量为4211.03万股，好仓比例升至5.00%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658298157","title":"康臣药业(01681.HK)拟8月26日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2658298157","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658298157?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:47","pubTimestamp":1786351622,"startTime":"0","endTime":"0","summary":"格隆汇8月10日丨康臣药业(01681.HK)宣布，公司将于2026年8月26日(星期三)举行董事局会议，以处理以下事项：1.审阅及批准公司及其附属公司截至2026年6月30日止六个月未经审核综合中期业绩；2.审阅及批准将根据香港联合交易所有限公司证券上市规则公布的中期业绩公告；3.考虑派发中期股息(如有)；及4.考虑及批准其他事项(如有)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260810/32330468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01681","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154908264","title":"康臣药业更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154908264","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154908264?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:46","pubTimestamp":1785836814,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司于2026年8月4日发布截至2026年7月31日的月度证券变动报告。公告显示，公司的法定股本及注册股本继续维持在5,000,000,000股，合计约5亿港元，与上月保持一致。截至2026年7月底，康臣药业已发行股份数量为839,049,111股，库存股份数量为2,498,000股，总发行股本数为841,547,111股，亦与上月持平。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651118884","title":"康臣药业首度入围中国医药工业百强 并获评“投资价值潜力企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651118884","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651118884?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:58","pubTimestamp":1783936709,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01681","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648652216","title":"光大证券：首予康臣药业(01681.HK)“买入”评级 目标价17.73港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648652216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648652216?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:33","pubTimestamp":1783067636,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","01681","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648655766","title":"【券商聚焦】光大证券首予康臣药业(01681)“买入”评级 指尿毒清颗粒增长空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2648655766","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648655766?lang=zh_cn&edition=full","pubTime":"2026-07-03 14:09","pubTimestamp":1783058947,"startTime":"0","endTime":"0","summary":"金吾财讯 | 光大证券发布研报指，康臣药业 是肾科中成药龙头企业，深耕肾科三十载，搭建了“1+6”产品矩阵。研报核心逻辑聚焦于公司旗舰产品尿毒清颗粒的广阔成长空间。作为独家品种，尿毒清颗粒循证医学证据充分，2025年实现营收22.79亿元，同比增长21%，稳居肾病中成药品类市场占有率第一。光大证券测算，尿毒清颗粒市场规模空间有望达到78-139亿元人民币，长期增长潜力充足。首次覆盖，给予“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985080","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681","601788"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191796556","title":"康臣药业发布2026年6月股份变动月报：当月回购2,039,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1191796556","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191796556?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:12","pubTimestamp":1782994344,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司于2026年7月2日公布2026年6月股份变动月报，报告期为截至2026年6月30日。公告显示，公司法定股本即注册股本维持不变，仍为5,000,000,000股普通股，注册股本总额500,000,000港元。已发行股份总数与上月底保持一致，均为841,547,111股，其中已发行股份于期末为839,049,111股，库存股份为2,498,000股。根据月报，康臣药业于2026年6月内通过一系列股份购回将2,039,000股转为库存股份，期间无新增发行、行使股份期权或注销股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135881530","title":"康臣药业集团有限公司：6月30日回购63,000股，涉资约79.16万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135881530","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135881530?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:22","pubTimestamp":1782822151,"startTime":"0","endTime":"0","summary":"康臣药业集团有限公司（股票代码：01681）6月30日发布翌日披露报表。公告显示，公司当日在香港联交所场内回购普通股63,000股，约占回购前已发行股本的0.0075%，每股回购价介乎12.50港元至12.58港元，总耗资约79.16万港元。\n本次回购后，公司已发行股本变动为839,049,111股，库藏股数量增至2,498,000股。此前回购授权于2026年5月26日获股东大会通过，授权总数为84,120,311股，公司迄今已回购2,154,000股，占该授权总数约2.5606%。\n公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由公司秘书高海恩签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康臣药业集团有限公司：6月30日回购63,000股，涉资约79.16万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647655593","title":"康臣药业(01681)6月30日斥资79.2万港元回购6.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647655593","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647655593?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:20","pubTimestamp":1782822058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康臣药业(01681)发布公告，于2026年6月30日斥资79.2万港元回购6.3万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01681","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinaconsun.com","stockEarnings":[{"period":"1week","weight":0.0036},{"period":"1month","weight":-0.0309},{"period":"3month","weight":-0.0246},{"period":"6month","weight":-0.1867},{"period":"1year","weight":-0.1184},{"period":"ytd","weight":-0.1077}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康臣药业集团有限公司是一家主要从事药品生产及销售业务的公司。该公司通过两个部门开展业务。康臣药业分部主要从事生产及销售现代中成药及医用成像对比剂业务。玉林制药分部主要从事生产及销售传统中成药业务。该公司的产品主要包括肾科药物、妇儿药物、对比剂、骨科药物、皮肤科药物、肝胆药物和其他。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.045405},{"month":2,"riseRate":0.538462,"avgChangeRate":0.016854},{"month":3,"riseRate":0.461538,"avgChangeRate":0.017226},{"month":4,"riseRate":0.692308,"avgChangeRate":0.059355},{"month":5,"riseRate":0.538462,"avgChangeRate":0.023091},{"month":6,"riseRate":0.384615,"avgChangeRate":-0.004071},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.002843},{"month":8,"riseRate":0.538462,"avgChangeRate":0.010796},{"month":9,"riseRate":0.615385,"avgChangeRate":0.026332},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.025897},{"month":11,"riseRate":0.5,"avgChangeRate":0.008662},{"month":12,"riseRate":0.583333,"avgChangeRate":0.021459}],"exchange":"SEHK","name":"康臣药业","nameEN":"CONSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康臣药业,01681,康臣药业股票,康臣药业股票老虎,康臣药业股票老虎国际,康臣药业行情,康臣药业股票行情,康臣药业股价,康臣药业股市,康臣药业股票价格,康臣药业股票交易,康臣药业股票购买,康臣药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康臣药业(01681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康臣药业(01681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}